Creation of Clear Regulatory Pathway Would Also Lower Total Expenditures for Biologics by $25 Billion Over Ten Years
June 25, 2008
PRNewswire-USNewswire
The Congressional Budget Office (CBO) today released a cost analysis finding that the creation of an abbreviated pathway for follow-on biologics — or biogenerics — would save the federal government $6.6 billion over ten years and lower total expenditures for biologics by $25 billion over the same time period.